权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

MECHANISMS OF BRAIN DYSFUNCTION IN TUBEROUS SCLEROSIS

结节性硬化症脑功能障碍的机制

基本信息

批准号：
9263020
负责人：
MICHAEL WONG
金额：
$ 33.36万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-08-21 至 2020-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9263020
关键词：
Address Affect Anti-Inflammatory Agents Anti-inflammatory Antiepileptogenic Astrocytes Autistic Disorder Benchmarking Brain Buffers Cells Cognitive deficits Complex Data Disease model Embryo Epilepsy Epileptogenesis FRAP1 gene Functional disorder Funding Gap Junctions General Population Genetic Glutamate Transporter Glutamates Grant Hereditary Disease High Prevalence Impaired cognition Impairment Inflammation Mediators Inflammatory Intellectual functioning disability Intervention Learning Disabilities Mediating Memory Mental Retardation Microglia Modeling Molecular Molecular Abnormality Morbidity - disease rate Mus National Institute of Neurological Disorders and Stroke Natural Immunity Neuroglia Neurologic Neurologic Deficit Neurologic Symptoms Neuronal Dysfunction Neurons Organ Pathogenesis Pathologic Pathway interactions Pharmacology Phenotype Play Population Research Potassium Process Property Public Health Publishing Research Role System TSC1 gene Testing Time Tuberous Sclerosis Tuberous sclerosis protein complex Work brain dysfunction cell type chemokine clinically significant cytokine disabling symptom improved inhibitor/antagonist innovation mortality mouse model nerve stem cell nervous system disorder neuron loss non-genetic novel novel therapeutic intervention novel therapeutics postnatal prevent public health relevance targeted treatment tumor

项目摘要

DESCRIPTION (provided by applicant): Tuberous sclerosis complex (TSC) is a genetic disorder, characterized by the formation of tumors in various organs, including the brain. Neurological manifestations, such as epilepsy, intellectual disability, and autism, are typically the most disabling symptoms of TSC. Advances in understanding the molecular pathogenesis of TSC have led to new therapies for tumors in TSC, particularly inhibitors of the mammalian target of rapamycin complex 1 (mTORC1) pathway. However, the pathophysiology of epilepsy and cognitive impairment in TSC is still poorly understood, and treatment of these disabling neurological symptoms remains limited. In previous funding periods of this grant, we utilized mouse models to investigate mechanisms of epileptogenesis in TSC (e.g. Tsc1GFAPCKO mice). We identified a number of cellular and molecular abnormalities in glia and neurons that contribute to epileptogenesis, such as astrocyte proliferation, impaired glial glutamate and potassium buffering, neuronal death, and dysregulation of mTORC1. Most remarkably, we provided evidence that mTORC1 inhibition has antiepileptogenic effects in preventing epilepsy and associated pathological abnormalities in mouse models of TSC, as well as in other models of acquired (non-genetic) epilepsy. In this grant renewal, we propose to extend our previous work by determining more specifically the contribution of non-neuronal cell types and innate immunity in contributing to the neurologic phenotype of TSC. Our general hypothesis is that non-neuronal cells, particularly astrocytes and microglia, play a critical role in the pathophysiology of epilepsy and other neurological manifestations of TSC, by activating inflammatory mechanisms in the brain. This proposal is innovative in focusing on the novel role of non-neuronal cells and innate immunity in the neurological phenotype of TSC. The proposal also has strong clinical significance and impact in testing new mechanistically-targeted therapies, which may benefit the neurological manifestations of not only TSC, but potentially also other neurological disorders.